- Home
- IMMX vs BEAT Comparison
IMMX vs BEAT Comparison
Compare IMMX & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- BEAT
- Stock Information
- Founded
- IMMX 2014
- BEAT 2015
- Country
- IMMX United States
- BEAT United States
- Employees
- IMMX N/A
- BEAT N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- IMMX Health Care
- BEAT Technology
- Exchange
- IMMX Nasdaq
- BEAT Nasdaq
- Market Cap
- IMMX 55.3M
- BEAT 65.1M
- IPO Year
- IMMX 2021
- BEAT 2021
- Fundamental
- Price
- IMMX $1.76
- BEAT $2.08
- Analyst Decision
- IMMX Strong Buy
- BEAT Buy
- Analyst Count
- IMMX 1
- BEAT 1
- Target Price
- IMMX $7.00
- BEAT $8.00
- AVG Volume (30 Days)
- IMMX 83.5K
- BEAT 132.5K
- Earning Date
- IMMX 03-28-2025
- BEAT 03-19-2025
- Dividend Yield
- IMMX N/A
- BEAT N/A
- EPS Growth
- IMMX N/A
- BEAT N/A
- EPS
- IMMX N/A
- BEAT N/A
- Revenue
- IMMX N/A
- BEAT N/A
- Revenue This Year
- IMMX N/A
- BEAT N/A
- Revenue Next Year
- IMMX $600.00
- BEAT N/A
- P/E Ratio
- IMMX N/A
- BEAT N/A
- Revenue Growth
- IMMX N/A
- BEAT N/A
- 52 Week Low
- IMMX $1.26
- BEAT $1.35
- 52 Week High
- IMMX $3.80
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- IMMX 31.71
- BEAT 39.34
- Support Level
- IMMX $1.85
- BEAT $2.05
- Resistance Level
- IMMX $2.14
- BEAT $2.37
- Average True Range (ATR)
- IMMX 0.12
- BEAT 0.18
- MACD
- IMMX -0.02
- BEAT -0.02
- Stochastic Oscillator
- IMMX 8.43
- BEAT 21.24
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.